Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: Results of a phase 2 consortium study
10.1016/S1470-2045(10)70203-5
Saved in:
Main Authors: | Bible, K.C., Suman, V.J., Molina, J.R., Smallridge, R.C., Maples, W.J., Menefee, M.E., Rubin, J., Sideras, K., Morris, J.C., McIver, B., Burton, J.K., Webster, K.P., Bieber, C., Traynor, A.M., Flynn, P.J., Goh, B.C., Tang, H., Ivy, S.P., Erlichman, C. |
---|---|
Other Authors: | PHARMACOLOGY |
Format: | Article |
Published: |
2016
|
Online Access: | http://scholarbank.nus.edu.sg/handle/10635/127090 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | National University of Singapore |
Similar Items
-
A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H
by: Bible, K.C., et al.
Published: (2016) -
A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer
by: Bible, K.C., et al.
Published: (2016) -
Phototoxic reaction induced by pazopanib
by: Siriorn Udompanich, et al.
Published: (2019) -
Response to a novel multitargeted tyrosine kinase inhibitor pazopanib in metastatic merkel cell carcinoma
by: Davids, M., et al.
Published: (2011) -
A phase II study of pazopanib in asian patients with recurrent/metastatic nasopharyngeal carcinoma
by: Lim, W.-T., et al.
Published: (2016)